Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. has a positive outlook due to its innovative product candidate, pemvidutide, which is a dual GLP-1/glucagon receptor agonist targeting obesity and metabolic diseases including metabolic dysfunction-associated steatohepatitis (MASH). The recent validation from Novo's acquisition of Akero Therapeutics highlights increasing interest in the MASH market and positions pemvidutide as a strategically relevant solution due to its leading tolerability profile and effective dual-action mechanism, which may simplify treatment regimens compared to combination therapies. Furthermore, alignment between preclinical data and clinical signals supports confidence in pemvidutide's potential to deliver significant clinical benefits, thereby enhancing Altimmune's standing in a rapidly evolving therapeutic landscape.

Bears say

Altimmune Inc faces several substantial risks that contribute to a negative outlook on its stock, primarily stemming from clinical development challenges associated with its investigational product candidate, pemvidutide. The company is also subjected to heightened competitor and commercialization risks, alongside potential reimbursement and pricing challenges that could hinder market entry and acceptance. Furthermore, external factors such as capital market volatility, possible dilution of shares, and disruptions from geopolitical events and health crises like COVID-19 could adversely affect the company's clinical trials and financial stability moving forward.

Altimmune (ALT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 6 analysts, Altimmune (ALT) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.